bcl-2 and MIB-1 labeling indexes in cats with lymphoma

Gillian Dank, Michael D. Lucroy, Stephen M Griffey, Regina F Gandour-Edwards, Bruce R. Madewell

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Immunohistochemistry was used to examine feline lymphoid tumors for bcl-2 and MIB-1 expression. Tumor tissues from 29 cats were selected to represent 2 groups - cats that did not respond to chemotherapy and cats that responded to therapy. Median bcl-2 immunoreactivity was 60%, and median MIB-1 reactivity was 47%. There was no significant difference in median survival time between cats with tumors with high levels of bcl-2 expression and those with low levels of expression. There was no significant difference in median survival time between cats with tumors with high levels of MIB-1 expression and those with low levels of expression. Mean bcl-2 immunoreactivity was significantly (P = .0004) higher in low-grade (73.2%) than in high-grade (16.9%) lymphomas, whereas the mean MIB-1 immunoreactivity was significantly (P = .0201) higher in high-grade (61.2%) lymphomas than in low-grade (35.0%) lymphomas. The mean bcl-2 immunoreactivity was significantly (P = .0042) greater in T-cell lymphomas (66.8%) than in B-cell lymphomas (22.8%). whereas the mean MIB-1 immunoreactivity was significantly (P = .0052) lower in T-cell lymphomas (36 4%) than in B-cell lymphomas (65.2%). Although expression of bcl-2 and MIB-1 did not appear to be linked to responses to chemotherapy in cats with lymphoma, the data suggest a possible role for these regulatory proteins in the biology of feline lymphomas.

Original languageEnglish (US)
Pages (from-to)720-725
Number of pages6
JournalJournal of Veterinary Internal Medicine
Volume16
Issue number6
StatePublished - Nov 2002

Fingerprint

lymphoma
Lymphoma
Cats
cats
Non-Hodgkin's Lymphoma
T-Cell Lymphoma
Felidae
B-Cell Lymphoma
Neoplasms
neoplasms
Drug Therapy
drug therapy
B-lymphocytes
T-lymphocytes
Immunohistochemistry
regulatory proteins
immunohistochemistry
Biological Sciences
therapeutics
Proteins

Keywords

  • Apoptosis
  • Cellular proliferation
  • Feline

ASJC Scopus subject areas

  • veterinary(all)

Cite this

bcl-2 and MIB-1 labeling indexes in cats with lymphoma. / Dank, Gillian; Lucroy, Michael D.; Griffey, Stephen M; Gandour-Edwards, Regina F; Madewell, Bruce R.

In: Journal of Veterinary Internal Medicine, Vol. 16, No. 6, 11.2002, p. 720-725.

Research output: Contribution to journalArticle

Dank, Gillian ; Lucroy, Michael D. ; Griffey, Stephen M ; Gandour-Edwards, Regina F ; Madewell, Bruce R. / bcl-2 and MIB-1 labeling indexes in cats with lymphoma. In: Journal of Veterinary Internal Medicine. 2002 ; Vol. 16, No. 6. pp. 720-725.
@article{844d047c146b4ba28c31561a1cf86f65,
title = "bcl-2 and MIB-1 labeling indexes in cats with lymphoma",
abstract = "Immunohistochemistry was used to examine feline lymphoid tumors for bcl-2 and MIB-1 expression. Tumor tissues from 29 cats were selected to represent 2 groups - cats that did not respond to chemotherapy and cats that responded to therapy. Median bcl-2 immunoreactivity was 60{\%}, and median MIB-1 reactivity was 47{\%}. There was no significant difference in median survival time between cats with tumors with high levels of bcl-2 expression and those with low levels of expression. There was no significant difference in median survival time between cats with tumors with high levels of MIB-1 expression and those with low levels of expression. Mean bcl-2 immunoreactivity was significantly (P = .0004) higher in low-grade (73.2{\%}) than in high-grade (16.9{\%}) lymphomas, whereas the mean MIB-1 immunoreactivity was significantly (P = .0201) higher in high-grade (61.2{\%}) lymphomas than in low-grade (35.0{\%}) lymphomas. The mean bcl-2 immunoreactivity was significantly (P = .0042) greater in T-cell lymphomas (66.8{\%}) than in B-cell lymphomas (22.8{\%}). whereas the mean MIB-1 immunoreactivity was significantly (P = .0052) lower in T-cell lymphomas (36 4{\%}) than in B-cell lymphomas (65.2{\%}). Although expression of bcl-2 and MIB-1 did not appear to be linked to responses to chemotherapy in cats with lymphoma, the data suggest a possible role for these regulatory proteins in the biology of feline lymphomas.",
keywords = "Apoptosis, Cellular proliferation, Feline",
author = "Gillian Dank and Lucroy, {Michael D.} and Griffey, {Stephen M} and Gandour-Edwards, {Regina F} and Madewell, {Bruce R.}",
year = "2002",
month = "11",
language = "English (US)",
volume = "16",
pages = "720--725",
journal = "Journal of Veterinary Internal Medicine",
issn = "0891-6640",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - bcl-2 and MIB-1 labeling indexes in cats with lymphoma

AU - Dank, Gillian

AU - Lucroy, Michael D.

AU - Griffey, Stephen M

AU - Gandour-Edwards, Regina F

AU - Madewell, Bruce R.

PY - 2002/11

Y1 - 2002/11

N2 - Immunohistochemistry was used to examine feline lymphoid tumors for bcl-2 and MIB-1 expression. Tumor tissues from 29 cats were selected to represent 2 groups - cats that did not respond to chemotherapy and cats that responded to therapy. Median bcl-2 immunoreactivity was 60%, and median MIB-1 reactivity was 47%. There was no significant difference in median survival time between cats with tumors with high levels of bcl-2 expression and those with low levels of expression. There was no significant difference in median survival time between cats with tumors with high levels of MIB-1 expression and those with low levels of expression. Mean bcl-2 immunoreactivity was significantly (P = .0004) higher in low-grade (73.2%) than in high-grade (16.9%) lymphomas, whereas the mean MIB-1 immunoreactivity was significantly (P = .0201) higher in high-grade (61.2%) lymphomas than in low-grade (35.0%) lymphomas. The mean bcl-2 immunoreactivity was significantly (P = .0042) greater in T-cell lymphomas (66.8%) than in B-cell lymphomas (22.8%). whereas the mean MIB-1 immunoreactivity was significantly (P = .0052) lower in T-cell lymphomas (36 4%) than in B-cell lymphomas (65.2%). Although expression of bcl-2 and MIB-1 did not appear to be linked to responses to chemotherapy in cats with lymphoma, the data suggest a possible role for these regulatory proteins in the biology of feline lymphomas.

AB - Immunohistochemistry was used to examine feline lymphoid tumors for bcl-2 and MIB-1 expression. Tumor tissues from 29 cats were selected to represent 2 groups - cats that did not respond to chemotherapy and cats that responded to therapy. Median bcl-2 immunoreactivity was 60%, and median MIB-1 reactivity was 47%. There was no significant difference in median survival time between cats with tumors with high levels of bcl-2 expression and those with low levels of expression. There was no significant difference in median survival time between cats with tumors with high levels of MIB-1 expression and those with low levels of expression. Mean bcl-2 immunoreactivity was significantly (P = .0004) higher in low-grade (73.2%) than in high-grade (16.9%) lymphomas, whereas the mean MIB-1 immunoreactivity was significantly (P = .0201) higher in high-grade (61.2%) lymphomas than in low-grade (35.0%) lymphomas. The mean bcl-2 immunoreactivity was significantly (P = .0042) greater in T-cell lymphomas (66.8%) than in B-cell lymphomas (22.8%). whereas the mean MIB-1 immunoreactivity was significantly (P = .0052) lower in T-cell lymphomas (36 4%) than in B-cell lymphomas (65.2%). Although expression of bcl-2 and MIB-1 did not appear to be linked to responses to chemotherapy in cats with lymphoma, the data suggest a possible role for these regulatory proteins in the biology of feline lymphomas.

KW - Apoptosis

KW - Cellular proliferation

KW - Feline

UR - http://www.scopus.com/inward/record.url?scp=0036835837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036835837&partnerID=8YFLogxK

M3 - Article

C2 - 12465771

AN - SCOPUS:0036835837

VL - 16

SP - 720

EP - 725

JO - Journal of Veterinary Internal Medicine

JF - Journal of Veterinary Internal Medicine

SN - 0891-6640

IS - 6

ER -